Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Exosome Diagnostics, a Bio-Techne brand logo — ExoDx Prostate is the only exosome-based, non-DRE, simple ur...

Exosome Diagnostics, a Bio-Techne brand

ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision.

Founded 2008 United States Waltham, United States 103 employees Series C Total: $112.08M Biotechnology, Health Care

General Information

Company Name Exosome Diagnostics, a Bio-Techne brand
Founded Year 2008
Location United States Waltham, United States +3
Founders / Decision Makers
Team member
Employees 103
Industries Biotechnology, Health Care
Funding Stage Series C
Social

Get notified when Exosome Diagnostics, a Bio-Techne brand moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Exosome Diagnostics, a Bio-Techne brand

Exosome Diagnostics, Inc., founded in 2008 and headquartered in the United States, is making significant strides in the biotechnology and healthcare industries. The company's slogan, "ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision," encapsulates its pioneering approach. Exosome Diagnostics is focused on commercializing minimally invasive molecular diagnostics in blood and urine, offering a breakthrough in guiding physicians to select optimal therapies for cancer and other diseases. The company's innovation lies in its utilization of exosomes, which are lipid bilayer-covered microvesicles shed by solid tumors into body fluids. These exosomes contain nucleic acid profiles of cancers and other diseases, serving as valuable indicators for diagnosis and treatment selection. Notably, Exosome Diagnostics has achieved compelling results in extracting exosomes from patients' blood and urine, detecting key genes and gene mutations associated with various cancers with high sensitivity and specificity. In their last funding round in July 2017, Exosome Diagnostics secured a substantial $30.00M Series C investment. This capital injection was provided by a distinguished group of investors including Forbion, Arcus Ventures, NGN Capital, Tiger Infrastructure Partners, b2venture (formerly btov Partners), CD-Venture, and Blue Ridge Capital. This financial backing is a testament to the confidence placed in Exosome Diagnostics' groundbreaking approach and its potential to revolutionize diagnostics and treatment selection in the healthcare industry.

Taxonomy: exosome-based diagnostics, liquid biopsy, prostate cancer, biopsy decision, molecular diagnostics, minimally invasive, nucleic acid profiles, cancer detection, urine test, blood test, cancer therapies, non-invasive testing, cancer biomarkers, precision medicine

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		24 Jul 2017
Series B •••••• 7
Investor Investor Investor Investor Investor
•••• •••• 		07 Jan 2016
Series B •••••• 5
Investor Investor Investor Investor
•••• •••• 		02 Sep 2015
Venture Round •••••• - 06 Jul 2015
Series B •••••• 7
Investor Investor Investor Investor Investor
•••• •••• 		11 Mar 2014

View All 6 Funding Rounds

Exosome Diagnostics, a Bio-Techne brand Alternatives & Competitors

Exosome Diagnostics, a Bio-Techne brand vs
miR Scientific, LLC
miR Scientific, LLC United States

miR Scientific is a healthcare company that is committed to transforming cancer management globally.

14 employees
Biotechnology, Health Care
Exosome Diagnostics, a Bio-Techne brand vs
GenoME Diagnostics Ltd
GenoME Diagnostics Ltd United Kingdom

Improving the ovarian cancer diagnostic pathway through earlier and more accurate diagnosis.

Seed
5 employees
Health Care
Compare Exosome Diagnostics, a Bio-Techne brand vs GenoME Diagnostics Ltd
Exosome Diagnostics, a Bio-Techne brand vs
ClearNote Health
ClearNote Health United States

Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthie...

57 employees
Also compare with: Exosome Diagnostics, a Bio-Techne brand vs Cellsway Cellsway Exosome Diagnostics, a Bio-Techne brand vs JaxBio JaxBio

FAQ About Exosome Diagnostics, a Bio-Techne brand

ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision.
Exosome Diagnostics, a Bio-Techne brand was founded in 2008.
Exosome Diagnostics, a Bio-Techne brand is headquartered in Waltham, United States.
Exosome Diagnostics, a Bio-Techne brand operates in the following industries: Biotechnology, Health Care.
Exosome Diagnostics, a Bio-Techne brand has approximately 103 employees.
Exosome Diagnostics, a Bio-Techne brand has completed 6 funding rounds, raising a total of $112.08M. The latest funding stage is Series C.
Top alternatives and competitors to Exosome Diagnostics, a Bio-Techne brand include miR Scientific, LLC, GenoME Diagnostics Ltd, ClearNote Health, Mirxes, Cellsway. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Exosome Diagnostics, a Bio-Techne brand and miR Scientific, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Exosome Diagnostics, a Bio-Techne brand and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy